What Is It and How Does It Work?
Upadacitinib is a once-daily pill that uses a technology called Oral Selective Janus Kinase (JAK) Inhibition. In conditions like Alopecia Areata, the body’s immune system mistakenly attacks hair follicles, forcing them into a dormant state where they cannot grow hair.
Inside your immune cells are tiny “communication switches” called Janus kinases. Upadacitinib works by specifically turning off the “JAK1” switch, which is the main signal used to coordinate the attack on your hair. By blocking this specific signal, the drug calms the immune system’s localized aggression, allowing the hair follicles to safely return to their natural growth cycle.
The Science and the Results
The submission to the FDA is based on a massive clinical program called UP-AA, which involved 1,399 patients aged 12 to 63 who had lost at least 50% of their hair.
To track how well the treatment worked, doctors used a tool called the SALT score, which stands for the Severity of Alopecia Tool. This is a standard medical scale from 0 to 100 used to measure the percentage of hair loss on the scalp. A SALT score of 100 means a person has lost all the hair on their scalp, while a score of 0 means they have no hair loss at all (100% hair coverage).
The clear results from the Phase 3 studies:
-
Total Hair Restoration: For the first time in a major trial, scientists tracked “complete regrowth” (a SALT score of 0). By week 52, up to 37% of patients on the 30 mg dose achieved 100% scalp hair coverage.
-
Substantial Recovery: Approximately 55% of patients reached a SALT score of 20 or less (which means 80% or more hair coverage) in just six months (24 weeks).
-
Early Action: Many patients saw the start of visible regrowth much earlier than with traditional treatments, with results continuing to improve steadily through the full year of the study.
“In the UP-AA clinical program, upadacitinib showed early and substantial scalp hair growth, including complete scalp hair coverage, which is a significant outcome for those living with this often-overlooked disease,” said Dr. Kori Wallace, a lead researcher for the program.
When Can You Get It?
The manufacturer, AbbVie, officially submitted the drug for approval on April 28, 2026. Because the drug is already proven and used for other conditions, the FDA review process is expected to move efficiently. Experts anticipate it will be available for doctors to prescribe specifically for hair loss by late 2026 or early 2027.
How you can benefit from this treatment now
The most important takeaway from this breakthrough is that “total regrowth” (a SALT score of 0) is now a realistic medical goal, not just a hope. While this specific pill is finishing its final regulatory hurdle, the medication itself is already FDA-approved and available in pharmacies for other conditions like severe eczema and arthritis. This means doctors are already very familiar with its safety profile. If you have severe autoimmune hair loss, you can talk to a dermatologist now about this new “Selective JAK” approach; they may be able to use current data to help you transition to these high-performance treatments as they become available.
